An open-label, proof-of-concept, Phase 2 trial evaluating safety and efficacy of Otlertuzumab in combination with bendamustine in patients with relapsed or refractory peripheral T-cell lymphomas (PTCL)
Phase of Trial: Phase II
Latest Information Update: 14 Nov 2018
At a glance
- Drugs Bendamustine (Primary) ; Otlertuzumab (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Proof of concept; Therapeutic Use
- 14 Nov 2018 According to an Aptevo Therapeutics financial report, results were presented.
- 13 Mar 2018 According to an Aptevo Therapeutics media release, the company anticipates to report preliminary data in Q4 2018.
- 08 Jan 2018 Status changed from planning to recruiting, according to an Aptevo Therapeutics media release.